Could a cancer drug help treat lewy body dementia?
NCT ID NCT04002674
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the safety and effects of nilotinib, a cancer drug, in 43 people with Dementia with Lewy Bodies (DLB). DLB is a common type of dementia that shares features with Parkinson's and Alzheimer's. The goal was to see if nilotinib is safe and changes brain biomarkers, not to cure the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMENTIA WITH LEWY BODIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Skin, speech, and brain scans may unmask hidden neurodegeneration
- Can sound waves soothe Dementia's emotional turmoil?
- Cancer drug shows promise for treating lewy body dementia
- Could tiny doses of radiation slow Alzheimer's? a new trial investigates
- Brain scans track Alzheimer's clues over decades
- Can a One-Time bone drug shield Parkinson's patients from fractures?